Vimarsana
Biggest News Aggregation in the World

Page 3 - Oxford Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oxford Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oxford Sciences Today - Breaking & Trending Today

Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature - Vimarsana News

Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature

Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature New method is being used by Nucleome to unlock the dark matter of the human genome for drug target discovery with exceptional precision Oxford, UK, 10 June 2021 – Nucleome Therapeutics (“Nucleome”), a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease, today announces the publication of a novel 3D geno

Source: yahoo.com
Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19 - Vimarsana News

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Date Time Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19 Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus. This breakthrough will improve understanding of how differences in DNA sequences can lead to increased risks of developing many different diseases. The method, which is around 1000 times more accurate than existing techniques, enables scientists to measure the cont...

How one of the UK's brightest startups lost its rights to the Oxford vaccine - Vimarsana News

How one of the UK's brightest startups lost its rights to the Oxford vaccine

How one of the UK’s brightest startups lost its rights to the Oxford vaccine Vaccitech is about to float for $700m in New York, but its vaccine heroics are a mere footnote in its prospectus for potential investors 18 April 2021 • 12:00pm At Oxford University, a long history of scientific triumph has often not been matched by commercial success. Its failure to exploit the discovery of antibiotics haunts the dreaming spires, according to Robin Wright, the chairman of the Covid vaccine developer Vaccitech. “A hundred years ago, they were the developers of Alexander Fleming’s big idea,”...

A Virtual Events Startup With $670 Million And The 19 Other Highest-Funded Forbes Under 30 Europe Honorees - Vimarsana News

A Virtual Events Startup With $670 Million And The 19 Other Highest-Funded Forbes Under 30 Europe Honorees

11:50pm EDT| A Virtual Events Startup With $670 Million And The 19 Other Highest-Funded Forbes Under 30 Europe Honorees Illustration by Alexander Wells for Forbes Share to Facebook These companies have all raised over $10 million in funding. While 2020 brought public life to a halt, venture capitalists cut checks at an unmatched volume. The 20 companies on 2021 30 Under 30 Europe Big Money list captured some the largest investments as all raised upwards of $10 million. These companies range from finance to science and all have an Under 30 honoree at the helm.  The list’s highest funded sta...

Source: forbes.com
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through ... - Vimarsana News

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through ... Vaccitech LimitedMarch 17, 2021 GMT OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includ...

Source: apnews.com